Loss of HER3-mediated resistance renders this subset particularly susceptible to HER2-targeting trastuzumab [43], which may be a potential therapeutic strategy for HNSCC with 3p arm loss and PIK3CA gain. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.